We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Spinal Fluid Liquid Biopsy May Help Clarify Uncertain Brain Tumor Findings

By LabMedica International staff writers
Posted on 28 Oct 2026

Brain and spinal cord tumors can be difficult to diagnose when imaging is inconclusive or tissue biopsy cannot be performed safely. More...

MRI changes may reflect cancer, inflammation, or treatment-related effects, while the blood-brain barrier can limit tumor DNA detection through blood-based liquid biopsy. Given these limitations, new research highlights cerebrospinal fluid DNA testing as a potential source of additional diagnostic information in challenging neuro-oncology cases.

Mayo Clinic (Rochester, MN, USA) researchers evaluated cerebrospinal fluid (CSF) cell-free DNA molecular profiling in patients with unresolved diagnostic questions involving the brain or spinal cord. The approach examines DNA fragments released by tumor cells into CSF, the clear fluid surrounding these structures. Samples collected by lumbar puncture are analyzed for individual gene changes and broader DNA patterns associated with tumors.

The study included 76 patients across three clinical scenarios: 35 had an undiagnosed brain or spinal cord abnormality, 21 had imaging changes that could indicate either tumor progression or treatment-related effects, and 20 were being evaluated for suspected leptomeningeal disease. This condition occurs when cancer spreads to the membranes and fluid surrounding the brain and spinal cord.

Tumor-associated DNA was detected in 20 patients, or 26% of the cohort. Samples from another 29 patients contained sufficient DNA for analysis but showed no tumor DNA, while 27 samples lacked enough usable DNA to complete testing. These results require careful interpretation, as the researchers noted that a negative finding did not rule out cancer: the amount of tumor DNA released into CSF can vary.

Published in the Journal of Neuro-Oncology, the findings concern a test that remains investigational. Tumor tissue remains the gold standard for definitive diagnosis when it can be obtained safely. To further develop the approach, researchers are working to improve analysis of low-DNA samples and determine whether tracking DNA changes and other biomarkers over time could help assess treatment response.

“Our goal is for CSF cell-free DNA testing to provide patients and their care teams with diagnostic insights when answers may otherwise be difficult to obtain. As we gain more experience, we hope it will also help connect patients with clinical trials and personalized treatment options,” said Cecile Riviere-Cazaux, a Mayo Clinic Alix School of Medicine student in Rochester and co-first author of the study.

Related Links
Mayo Clinic


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Connectivity Solution
EKF Link
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.